Randomized Trialhigh evidence
Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England)·September 24, 2026·PMID 42785338
Why it mattersIrritable bowel syndrome is common and often refractory to current treatments, and gut microbiota alterations have been implicated in its pathogenesis. This large, well-designed trial provides high-level evidence that a single FMT enema does not improve IBS symptoms, suggesting that microbiota modulation alone may be insufficient.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled